Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
170 hedge funds and large institutions have $1.98B invested in Acceleron Pharma in 2018 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 60 increasing their positions, 38 reducing their positions, and 14 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
143% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 14
58% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 38
24% more capital invested
Capital invested by funds: $1.59B → $1.98B (+$389M)
13% more funds holding
Funds holding: 150 → 170 (+20)
49% less call options, than puts
Call options by funds: $32.5M | Put options by funds: $64.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$44.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24.1M |
| 3 |
DM
Deerfield Management
New York
|
+$18.6M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$15.8M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.7M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$27.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$21.1M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$16.4M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$12.3M |
XLRN Hedge Fund Activity: Q2 2018 in Review
170 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2018, worth a combined $1.98B — up 24% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new XLRN positions and 14 closed out — a net gain of 20 holders — while 60 added to existing stakes and 38 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $44.9M. The largest seller was Fidelity Investments, cutting an estimated $27.7M.
- 170 institutional investors held Acceleron Pharma (XLRN) as of Q2 2018, up from 150 in Q1 2018.
- Funds reported $1.98B of Acceleron Pharma stock for Q2 2018, up 24% quarter-over-quarter.
- 34 funds opened new Acceleron Pharma positions in Q2 2018 and 14 closed out, a net change of +20 holders.
- The largest Acceleron Pharma buyer in Q2 2018 was Janus Henderson Group, an estimated $44.9M added.
- The largest Acceleron Pharma seller in Q2 2018 was Fidelity Investments, an estimated $27.7M sold.
Based on aggregated 13F filings for Q2 2018.